

bloodstream or into the interstitium of the organism to undergo therapy.

B1

220. (New) Use according to claim 188, where the dsRNA is taken up into bacteria or microorganisms.

REMARKS

It is noted that during the International Phase new claims 1-125 were filed on April 9, 2001, in accordance with PCT Article 34. Then claims 3-7, 10-31, 34-38, 41-61, 65-80, 83-87, 90-110, 112-113, 116-118, and 121-125 were amended by the Preliminary Amendment filed July 20, 2001. Claims 1-125 are now being cancelled and replaced by claims 126-220.

New claim 126 is based on the original claims 1, 5 and 13. New claim 157 comprises the features of the original claims 37, 41 and 49. New claim 188 is based on original claims 74, 86 and 112. Further claims 157 and 188 comprise the figure "in mammalian cells" which is disclosed in the International publication WO 00/44895 on page 8, line 16. The original claims 2, 5, 13-15, 38, 41, 49-52, 75, 78, 86-88 and 112 have been removed. Further all features being directed to a vector and a single strand, namely a closed or a hairpin dsRNA, have been cancelled. In new claims 185 and 216 the features been directed to a vertebrate cell have been cancelled. New claim 218 has been corrected in that the word "method" has been replaced by the word "use".

If any fees are required by this communication, please charge such fees to our Deposit Account No. 16-0820, Order No. 33796.

Respectfully submitted,

PEARNE & GORDON LLP

By John P. Murtaugh  
John P. Murtaugh, Reg. No. 34226

526 Superior Avenue East  
Suite 1200  
Cleveland, Ohio 44114-1484  
(216) 579-1700

Date: Sept. 11, 2002